Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 5/20 | 0.59 |
| ▸ | PLAU | P00749 | 2/20 | 0.59 |
| ▸ | BACE1 | P56817 | 2/20 | 0.59 |
| ▸ | MCHR1 | Q99705 | 11/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 1/20 | 0.45 |
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31683661 | 0.78 | SLC40A1 (0.42) | NCF1PLAUBACE1MCHR1SMN1; SMN2 | |
| SCHEMBL1967396 | 0.78 | SLC40A1 (0.42) | NCF1PLAUBACE1MCHR1SMN1; SMN2 | |
| SCHEMBL21975961 | 0.77 | NCF1 (0.63) | NCF1PLAUBACE1MCHR1NOS2 | |
| SCHEMBL28088094 | 0.76 | BACE1 (0.45) | NCF1PLAUBACE1MCHR1NOS2 | |
| SCHEMBL6845198 | 0.75 | NCF1 (0.58) | NCF1PLAUBACE1MCHR1NOS2 | |
| SCHEMBL378207 | 0.74 | METAP2 (0.59) | SMN1; SMN2 | |
| SCHEMBL15228915 | 0.74 | BACE1 (1.00) | NCF1PLAUBACE1MCHR1NOS2 | |
| SCHEMBL361523 | 0.74 | NCF1 (1.00) | NCF1PLAUBACE1MCHR1 | |
| SCHEMBL1967101 | 0.74 | PFKFB3 (0.42) | NCF1PLAUSMN1; SMN2 | |
| SCHEMBL30035233 | 0.74 | NCF1 (0.59) | NCF1PLAUBACE1MCHR1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11952380-B2 | Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors | LUPIN LIMITED (IN) | 2024-04-09 | — | — | US | disclosed |
| CN-111712498-B | Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors | 鲁平有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-11198699-B2 | Compounds targeting PRMT5 | ALIGOS THERAPEUTICS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11198699-B2 | Compounds targeting PRMT5 | PRMT5, PRMT1, PRMT6 | NCF1 3116/4885PLAU 3140/4885BACE1 2330/4885 |
| US-11952380-B2 | Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | NCF1 3660/4885PLAU 3657/4885BACE1 1210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.